The FDA said retailers were first notified of the recall November 8, after health officials determined the formula was the likely source of the outbreak. The company expanded the recall to all ByHeart ...

Odds of vertebral compression fractures or surgical intervention were significantly lower among GLP-1 RA users ...

Since 1991, the CDC had recommended that all newborns receive a hepatitis B shot within 24 hours of birth to prevent early infections. The change follows a vote earlier this month by the CDC’s vaccine ...

The Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa), an interleukin-5 antagonist, for add-on maintenance treatment of severe asthma characterized by an eosinophilic ...

Fasedienol is a first-in-class pherine nasal spray that is designed to modulate the olfactory-limbic amygdala fear and anxiety neurocircuits.

The Viaskin Peanut patch showed clinically meaningful desensitization and a favorable safety profile in young children with peanut allergy.

Two phase 3 trials evaluating a subcutaneous (SC) formulation of efgartigimod (efgartigimod alfa and hyaluronidase-qvfc ), a neonatal Fc receptor blocker, ...

GLP-1 RA therapy linked to significantly lower risk for epilepsy compared with DPP4-i use among adults with T2DM ...

The approval was based on a randomized, double-blind, placebo-controlled phase 3 trial, which included 447 postmenopausal women with acquired, generalized HSDD.

Lerochol is an adnectin-based, small protein-binding, third generation proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.

The pivotal phase 3 RINGSIDE trial investigated varegacestat, an oral gamma secretase inhibitor, in patients with progressing desmoid tumors.

Patients should be selected for treatment with Enhertu in combination with pertuzumab based on confirmed HER2-positive status or HER2 gene amplification (IHC 3+ or ISH+).